Vaishali Pharma Ltd
Incorporated in 1989, Vaishali Pharma Ltd
does marketing of pharmaceutical products including active pharmaceutical ingredients[1]
- Market Cap ₹ 93.5 Cr.
- Current Price ₹ 7.17
- High / Low ₹ 13.6 / 4.75
- Stock P/E 22.5
- Book Value ₹ 5.30
- Dividend Yield 0.00 %
- ROCE %
- ROE 6.02 %
- Face Value ₹ 2.00
Pros
Cons
- Promoter holding is low: 31.6%
- Earnings include an other income of Rs.3.84 Cr.
- Company has high debtors of 170 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2026 | |
|---|---|
| 109 | |
| 105 | |
| Operating Profit | 4 |
| OPM % | 4% |
| 4 | |
| Interest | 2 |
| Depreciation | 1 |
| Profit before tax | 5 |
| Tax % | 25% |
| 4 | |
| EPS in Rs | 0.32 |
| Dividend Payout % | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 14% |
| 3 Years: | -19% |
| 1 Year: | -43% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | 6% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2026 | |
|---|---|
| Equity Capital | 26 |
| Reserves | 43 |
| 19 | |
| 35 | |
| Total Liabilities | 123 |
| 2 | |
| CWIP | 0 |
| Investments | 6 |
| 116 | |
| Total Assets | 123 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2026 | |
|---|---|
| Net Cash Flow | |
| Free Cash Flow | |
| CFO/OP |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2026 | |
|---|---|
| Debtor Days | 170 |
| Inventory Days | 13 |
| Days Payable | 81 |
| Cash Conversion Cycle | 102 |
| Working Capital Days | 212 |
| ROCE % |
Insights
In beta| Mar 2017 | Mar 2019 | Aug 2020 | Feb 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| Number of Countries Presence Number |
|
||||
| Number of Approved Product Registrations Number |
|||||
| Number of Customers Number |
|||||
| Number of Employees Number |
|||||
| Number of Registered Brands Number |
|||||
| Number of Brands in Pipeline Number |
|||||
| Number of Manufacturing Sites (Third Party) Number |
|||||
| Pending Order Book INR Crores |
|||||
| Pending Order Book (Formulations/Export) INR Crores |
|||||
| Total Number of Products Number |
|||||
Extracted by Screener AI
Documents
Announcements
-
Shareholders meeting
3 June 2026 - Postal ballot runs June 4-July 3, 2026 for reappointments and CFO pay hike to ₹24 lakh.
-
Copy of Newspaper Publication
3 June 2026 - Board approved audited Q4 and FY2026 results on 30 May 2026; newspaper advertisement published.
-
Outcome of Board Meeting
30 May 2026 - Board approved audited standalone and consolidated FY2026 results on 30 May 2026.
-
Outcome of Board Meeting
23 May 2026 - Board approved reappointment of MD Atul Vasani, WTD Jagruti Vasani and independent director Pratik Jakhelia for 5 years.
-
Price movement
22 April 2026 - Vaishali Pharma says price movement is market-driven, with no undisclosed material information.
Annual reports
Concalls
-
Feb 2024Transcript PPT
-
Nov 2023Transcript PPT
-
Aug 2020TranscriptAI SummaryPPT
-
May 2020TranscriptAI SummaryPPT
Business Overview:[1]
VPL is certified by ISO 9001:2008 and provides 1500+ products and 250+ Brands including APIs, Formulations, Surgical, Herbals, Veterinary, Nutraceutical, Oncology, and other healthcare products in 35+ locations